Sagimet Biosciences Inc (NASDAQ: SGMT) is -10.00% lower on its value in year-to-date trading and has touched a low of $2.39 and a high of $11.76 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The SGMT stock was last observed hovering at around $4.31 in the last trading session, with the day’s loss setting it -0.26%.
Currently trading at $4.05, the stock is -12.76% and -16.59% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.95 million and changing -6.03% at the moment leaves the stock -4.31% off its SMA200. SGMT registered -62.04% loss for a year compared to 6-month gain of 20.90%. The firm has a 50-day simple moving average (SMA 50) of $4.8948 and a 200-day simple moving average (SMA200) of $4.23815.
The stock witnessed a -20.28% loss in the last 1 month and extending the period to 3 months gives it a -27.55%, and is -4.71% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.39% over the week and 12.67% over the month.
Sagimet Biosciences Inc (SGMT) has around 10 employees, a market worth around $124.23M and $0.00M in sales. Distance from 52-week low is 69.46% and -65.56% from its 52-week high. The company has generated returns on investments over the last 12 months (-21.98%).
The EPS is expected to grow by 44.05% this year, but quarterly earnings will post -100.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
81.0 institutions hold shares in Sagimet Biosciences Inc (SGMT), with institutional investors hold 77.94% of the company’s shares. The shares outstanding are 30.67M, and float is at 20.41M with Short Float at 23.44%. Institutions hold 66.94% of the Float.
Sagimet Biosciences Inc (SGMT) Insider Activity
The most recent transaction is an insider sale by Kemble George, the company’s Executive Chairman. SEC filings show that Kemble George sold 23,625 shares of the company’s common stock on Jul 23 ’24 at a price of $3.17 per share for a total of $74830.0. Following the sale, the insider now owns 0.12 million shares.
Sagimet Biosciences Inc disclosed in a document filed with the SEC on Jul 19 ’24 that Martins Eduardo Bruno (Chief Medical Officer) sold a total of 8,357 shares of the company’s common stock. The trade occurred on Jul 19 ’24 and was made at $3.10 per share for $25910.0. Following the transaction, the insider now directly holds 81213.0 shares of the SGMT stock.
Still, SEC filings show that on Jul 19 ’24, Rozek Elizabeth (General Counsel and CCO) disposed off 10,914 shares at an average price of $3.10 for $33830.0. The insider now directly holds 160,506 shares of Sagimet Biosciences Inc (SGMT).
